Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for PAS-004 in Advanced cancer. The expected timing is based on the latest available company guidance and may change.
4/29/25- Completed enrollment & initiated dosing in Cohort 6. 5/6/25- Reported interim PD data. 5/14/25- Initiated Ph1/1b trial. 6/2/25- Presented interim data at ASCO '25. 7/31/25- Enrollment of first cohort completed. Initial interim in Q1 2026. 9/8/25- Announces enrollment of cohort 2. 01/13/26:- Advanced cancer Ph1 trial NCT06299839 longer-term follow-up data from cohorts 4-8 expected Q2 2026. 06/30/26:- Reported interim Ph1 NCT06299839 safety/PK and stable disease; protocol amended for higher doses and food-effect study. 07/21/26:- ESMO 2026 poster with Ph1 safety/PK results scheduled Oct 23, 2026.
Verification
Confirm timing and program details against the company announcement or filing.